Edition:
India

3Sbio Says Clinical Trial Application Approved By National Medical Products Administration


Thursday, 1 Aug 2019 

Aug 1 (Reuters) - 3SBio Inc <1530.HK>::CLINICAL TRIAL APPLICATION OF RECOMBINANT HUMANIZED ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY INJECTION SOLUTION APPROVED BY NMPA.NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED GROUP'S APPLICATION ON 31 JULY 2019. 

Company Quote

12.46
0.04 +0.32%
20 Nov 2019